Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report.

COVID-19 T cell angioimmunoblastic follicular lymphoma mRNA vaccine

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2021
Historique:
received: 19 10 2021
accepted: 08 11 2021
entrez: 13 12 2021
pubmed: 14 12 2021
medline: 14 12 2021
Statut: epublish

Résumé

Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein, we report and discuss unexpected rapid progression of lymphomatous lesions after administration of a BNT162b2 mRNA vaccine booster in a man recently diagnosed with AITL.

Identifiants

pubmed: 34901098
doi: 10.3389/fmed.2021.798095
pmc: PMC8656165
doi:

Types de publication

Case Reports

Langues

eng

Pagination

798095

Informations de copyright

Copyright © 2021 Goldman, Bron, Tousseyn, Vierasu, Dewispelaere, Heimann, Cogan and Goldman.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cancer Med. 2020 Aug;9(15):5509-5518
pubmed: 32558387
Cell Rep. 2017 Nov 7;21(6):1624-1638
pubmed: 29117566
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Nat Genet. 2014 Feb;46(2):171-5
pubmed: 24413737
Acad Radiol. 2021 Aug;28(8):1058-1071
pubmed: 33985872
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
Clin Nucl Med. 2022 Jan 1;47(1):e89-e90
pubmed: 34269722
Clin Nucl Med. 2021 Oct 1;46(10):814-819
pubmed: 34115709
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1854-1863
pubmed: 33774684
JAMA. 2021 Jul 6;326(1):46-55
pubmed: 34081073
Cancer Cell. 2018 Feb 12;33(2):259-273.e7
pubmed: 29398449
Clin Transl Imaging. 2021 May 13;:1-6
pubmed: 34007835
Clin Nucl Med. 2021 Apr 1;46(4):353-354
pubmed: 33591026
J Exp Med. 2018 Jun 4;215(6):1571-1588
pubmed: 29739835
Clin Nucl Med. 2021 Dec 1;46(12):1011-1012
pubmed: 34735411
Pharmaceuticals (Basel). 2021 Aug 03;14(8):
pubmed: 34451859
Radiology. 2021 Jul;300(1):E296-E300
pubmed: 33625300

Auteurs

Serge Goldman (S)

Department of Nuclear Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Dominique Bron (D)

Department of Hematology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.

Thomas Tousseyn (T)

Department of Pathology, UZ Leuven Hospitals, Leuven, Belgium.

Irina Vierasu (I)

Department of Nuclear Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Laurent Dewispelaere (L)

Laboratory of Hematology, LHUB, Université Libre de Bruxelles, Brussels, Belgium.

Pierre Heimann (P)

Laboratory of Hematology, LHUB, Université Libre de Bruxelles, Brussels, Belgium.

Elie Cogan (E)

Department of Internal Medicine, CHIREC Hospital, Brussels, Belgium.

Michel Goldman (M)

I3h Institute, Université Libre de Bruxelles, Brussels, Belgium.

Classifications MeSH